OptimizeRx Co. (NASDAQ:OPRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $9.06.

A number of brokerages have recently commented on OPRX. JMP Securities lowered their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday, November 14th. B. Riley lowered their target price on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. Roth Mkm restated a “buy” rating and set a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Lake Street Capital reiterated a “buy” rating and set a $11.00 price objective on shares of OptimizeRx in a research note on Tuesday, December 24th. Finally, Stephens initiated coverage on OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price for the company.

Insider Buying and Selling at OptimizeRx

In related news, CEO William J. Febbo purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, with a total value of $100,200.00. Following the purchase, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This trade represents a 3.44 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of OptimizeRx

A number of hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its holdings in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares during the period. Quest Partners LLC grew its position in OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares in the last quarter. SG Americas Securities LLC acquired a new stake in OptimizeRx during the 4th quarter valued at $51,000. Barclays PLC lifted its holdings in shares of OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of OptimizeRx in the second quarter worth $282,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $5.55 on Tuesday. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65. The company has a market cap of $102.23 million, a PE ratio of -4.17 and a beta of 1.36. The stock has a 50 day simple moving average of $5.19 and a 200-day simple moving average of $6.68. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.